Evidence map›Paper›PMID 30357465›Full record

ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2019

[Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].

Gregor Kastl

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gregor KastlAugenklinik Herzog Carl Theodor, Nymphenburger Str. 43, 80335, München, Deutschland. gregor-kastl@gmx.de.
Blindeninstitutsstiftung · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Under a combination therapy with cobimetinib/vemurafenib for the treatment of BRAF-V600 positive metastatic melanoma, symptomatic or asymptomatic bilateral serous retinopathy can occur, which is reversible after dose reduction or treatment discontinuation. In the case presented the progress of bilateral serous retinopathy was documented by optical coherence tomography (OCT). After therapy discontinuation, subfoveal fluid levels varied until remission was reached six months later.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzetidinesIndolesMelanomaMutationPiperidinesProto-Oncogene Proteins B-rafSulfonamidesVemurafenibAzetidinescobimetinibIndolesPiperidinesProto-Oncogene Proteins B-rafSulfonamidesVemurafenibBRAF-V600 mutationCobimetinibMetastatic melanomaSerous retinopathyVemurafenib

Identifiers

PMID30357465
OpenAlexW2898253099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.